The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications. In a letter dated March 5 and made ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

The FDA has issued warnings to 30 telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between ...

A new oral version of the weight loss drug Wegovy has been approved by the FDA, offering a more affordable and accessible ...

The Food and Drug Administration’s crackdown on cheaper, independently produced versions of popular weight-loss and diabetes medications stoked anger and pushback from users, sellers and the Alliance ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...